We were up .6% last week and are now up 13.5% for the year
Some of our stocks are just stupid cheap—compared to their net cash on hand per share divided by their stock price.
Check this list:
Plus EXTR, RIMG, ANGN and MRVC.PK are all in “play” with activist shareholders either trying to get them to pay out special dividends or take them over, or they are pursuing “strategic alternatives”.
The DOW was down 1% last week, NASDAQ was up .7% and the S+P 500 was down .6%. The Russell 3000 was down .5%.
AVNW, CBEY, MTSL, GRVY, LXK and MITL are our favorites.
MITL earnings last week.
For the year, the DOW is now back up 3.5%, NASDAQ is up 11%, S+P 500 is up 6.2%, and the Russell 3000 is up 6%
Last week we went 10 stocks up, 12 down and 2 unchanged. Since inception we are now 56 stocks up and 18 down for a 75.7% winning percentage (80% is our target win %).
Since our beginning, we have closed out the following positions:
2006-ONXS +11% (Buyout offer)
2006-CAW +21% (Buyout offer)
2007-IYXI.ob +44% (Buyout offer)
2007-MOBI +47% (Buyout offer)
2007-INFT +11% (Buyout offer)
2007-DTLK +25% (2 weeks)
2007-PDLI + 3%
2007-LINN.ob -57% (mortgage business bust didn’t help here)
2007-TISA -39% (take some tax loss for 2007 due to disappointing results.
2008-OPTO.ob +40% (Buy-out offer)
2008-PDLI +9% (company split, and special dividend)
2008-BDAY -39% (long overdue takeover offer-or “take-under”)
2008-DTLK +40% (third trip on this one)
2008-ILOG +26% (Buy-out offer from IBM)
2009-HSTM +67% (continued good earnings)
2009-CLZR -32% (a loser even on a buy-out)
2009-DTLK +28% (our 5th profitable trip on this one)
2010-CHRD +37% Buyout (2 weeks after we recommended it)
2010-CAW EVEN (excluding 2.5 years of dividends)
2011-PRM +56% Buyout (1 week after we recommended it)
The model portfolio assumes $10,000 invested in each stock (unless we double-up–then it is $20,000), less $10 commission each way (TD Ameritrade rate).
For the 50 stocks that we closed out since 2006 (45 were winners) the average net gain was 38%.
Telecommunications Systems Inc. (NASDAQ-AVNW)-Recommended 6/14/2012)
Buy Price- $1.37
Closed down $.04 at $1.34
TSYS announced in June that they were writing off $126 million of goodwill. No cash impact to this although they will show a big loss for Q2.
Down 2%, BUY
Aviat Networks Inc. (NASDAQ-AVNW)-Recommended 2/27/2012)
Buy Price- $2.62
Valuation $8.85 (Was $8.31)
Closed up $.04 at $2.92
Earnings out in May. Revenues were down $4 million to $111.6 million, but they made $2.2 million on a Non-GAAP basis versus losing $.4 million last year.
Our valuation rose to $8.85 and cash per share rose to $1.53.
Up 12%, BUY
CBeyond Inc. (NASDAQ-CBEY)-Recommended 2/28/2012)
Buy Price $7.17- ( Was $7.94 before another $10,000 added at $6.53)
Valuation $29.58 (Was $29.21)
Closed down $.22 at $6.27
Earnings out in May Revenues were up $5 million to $124 million and they lost $1.2 million versus $.14 million last year. EBITDA was up $4 million to $23 million. We continue to think this is way undervalued and are adding another $10,000 here.
Our valuation inched up to $29.58.
Down 13%, BUY
MRV Communications (Pink Sheets-MRVC.pk)
Valuation $1.73 (Was $2.06, $2.16 (after $.0475 and $.30 special dividends), $2.62, $2.79)
Buy Price October 7, 2011- $.50 ($1.27 before special dividends)
Closed at $.66 up $.02
MRV announced that they had settled a lawsuit related to a past acquisition and will pay $2.3 million, but get a $2.2 million gain this quarter as the settlement was less than they had booked.
The $.30 special dividend was paid in June
Raging Capital continues to buy shares. They now own over 27 million shares or 17.6% of MRV.
Earnings announced in May. All numbers have been restated for the CES sale in Q1.
Sales fell from $53 million to $48 million and the lost about $3.5 million pre-tax (after taking out stock compensation and a CFO severance charge). MRV declared another special dividend last week. $.30 a share this time. This will leave them with about $47 million of cash or another $.29 a share. Our valuation fell to $1.73 per share. Cash was $.59 per share. After the special dividend payable this month, our adjusted valuation will be $1.43 and assuming the stock price falls by the same amount, the stock will be trading at about 50% of our valuation.
Up 13% HOLD
Sigma Designs Inc. (NASDAQ-SIGM)-Recommended 7/11/2011)
Valuation $10.67 (Was $8.41 $12.10, $13.40, $16.02)
Closed up $.06 at $6.34
Good news, SIGM terminated its shareholder rights agreements and named a new Chairman of the Board. Maybe they are clearing the way to be sold?
Earnings announced in May. Still losing money but sales were up to $40 million from $36 million last quarter. They lost $8.5 million on a non-GAAP basis versus $14 million last quarter. Net cash per share fell a bit to $4.32. Over all our valuation increased about 25% to $10.67. Not bad, but not good enough to buy any more here.
They are projecting sales for next quarter (Q2) to be between $61-$67 million with 45% GAAP margins. Operating breakeven is expected in Q4 including the Trident acquisition which is expected to contribute about $24 million of sales per quarter.
So we are trading at a market cap of about $45 million (excluding cash) for a $$200 million a year chip company with 50% margins. Still pretty stupid we think. We plan to hold on for another couple of quarters to see if they can turn this around.
Down 25%, HOLD
Mitel Networks (NASDAQ-MITL)-Recommended 7/6/2011)
Buy Price- $3.04( Was $3.36 before $10,000 added, $3.95 before $10,000 added)
NEW Valuation $13.92 (Was $12.81, $15.28, $14.04, $10.39)
Closed up $.19 at $4.39
Earnings announced last week. Another very good quarter. Sales were up about 4% to $158 million and they made $17.1 million of income on a Non-GAAP basis. Our valuation rose to $13.92. MITL appears to be running on all eight cylinders now.
Up 45%, BUY
Rimage (NASDAQ-RIMG)-Recommended 5/24/2011)
Valuation $$19.81 (Was $22.23, $25.63, $26.45)
Closed down $.47 at $7.79
Pays $.68 a share annual dividend.
We have collected $.54 of dividends since we recommended RIMG.
Another lousy quarter. Sales down 9% to $19.5 million and they lost $3 million on an operating basis. Cash fell to $66.8 million or $6.52 and our valuation fell again to $16.73.
This is the worst case of management squandering its assets on an acquisition to escape being bought out and fired. We have lost almost $10 on our valuation and the stock is down almost 40%. Qumu sales were $1.4 million. Spent over $40 million to buy this paltry revenue stream.
Guidance for 2012 is low double digit sales growth and the same level cash flow. Teetering on selling here despite the yield.
Down 45%, HOLD
Lexmark International (NYSE-LXK)-Recommended 5/24/2011)
Valuation $62.59 (Was $63.94, $63.84, $79.12, $63.99)
Closed up $.37 at $25.91
We have also collected $.80 a share in dividends here.
LXK upped their dividend to $.30 a quarter.
Earnings announced in April. Revenues were $992 million and they made $1.05 per share on a non-GAAP basis. Net cash fell to $4.31 per share due to acquisitions, dividends and stock buybacks of $260 million. Fully diluted shares outstanding were 72.3 million compared to 79.8 million when we recommended LXK. Our valuation fell to $62.59. Analysts were disappointed, so down went the stock.
They reiterated their intent to return over 50% of their free cash flow to shareholders in dividends and share repurchases. The vagaries of the stock analysts make us cautious but we are back down below our original buy price so we are making this a Buy again.
Down 10%, BUY
MER Telemanagement (NASDAQ-MTSL)-Recommended 5/17/2011)
Buy Price-$1.42 (Was $1.50 before adding another $10,000 investment)
Valuation $5.77 (Was $5.55, $6.28 $5.61, $5.11)
Closed down $.03 at $1.68
Earnings announced in May. Sales were up from $2.8 million to $3 million and they made $.07 per share versus $.03 last year. With $.80 a share in cash, this is trading at about 4X annualized earnings. Way too cheap. Our valuation rose to $5.77 per share.
Up 18% BUY
Harris Interactive (NASDAQ-HPOL)-Recommended 3/3/2010)
Valuation $3.15 (Was $3.05, $2.90, $3.11, $2.63, $2.97)
Closed at $1.22, up $.14
Earnings announced in May. Sales dropped $3 million from $37 million to $34 million. Their loss was slashed from $2.3 million to $.3 million. Not bad. Our valuation rose to $3.15 per share. If they can get some sales momentum over the next couple of quarters we could see $2 plus. If……..
EVP purchased 12,500 shares in March at $1.03 and interim CFO bought 11,000 shares at $1.02.
Up 33%, HOLD
Concurrent Computer (NASDAQ-CCUR)-Recommended 2/4/2011)
Valuation $15.85 (was $14.13, $11.38, $14.04, $18.54, $15.99)
Closed down $.12 at $3.88
13D/A filed last week disclosing another 100,000 shares purchased on June 13th by the Singer/Miller group for $3.75. Their combined ownership is now 11.7%.
Singer is also involved in MRV and was involved with Evolving Systems (which we owned personally even though we didn’t recommend it—it was a huge winner).
Earnings announced in May. Not bad. Revenues were down $2 million to $16.3 million but they made $.04 per share. Cash fell to $2.61 per share as receivables rose. Our valuation rose to $15.85, the second quarter of rising valuation and just about back to when we recommended it. Now the price just needs to reflect the improvement.
Down 24%, HOLD
Astex Pharmaceuticals Inc. (Was SuperGen Inc.) (NASDAQ-ASTX)-Recommended 10/4/2010)
Buy Price-$2.31 (was $2.09 before adding $10,000)
Valuation $3.44 (was $3.42, $3.22, $3.11, $5.21, $4.89, $4.37, $3.48)
Closed up $.15 at $2.10
Earnings announced in May. Pretty good. Cash was $1.21 per share. Revenues spiked to $22 million from $17 million last year and they made $.04 per share on a GAAP basis compared to $.09 last year. They are still forecasting $65- $68 million in revenues for the year and losing $13-$15 million on a GAAP basis. Cash burn looks like about $5 million for the year.
So we have a company losing maybe $5 million in cash a year, or 25 years of cash, about $70 million in revenues and a huge drug pipeline. Any good news on the clinical trials front ought to set this stock on fire.
As we said before, the merger with the revenue poor Astex hurt our valuation which does not take into account the massive drug pipeline of Astex. It is not easy to find a small drug company that has a pile of cash, is not losing a ton of money and is trading at even close to our valuation.
There are $2 BILLION of potential milestone payments down the road.
Down 9%, HOLD
Performance Technology (PTIX-Recommended 3/30/2010)
Valuation $6.01-(was $6.17, $5.94, $4.87, $4.99, $3.79, $3.87, $5.03, $5.98, $7.13)
Closed down $.14 at $2.03
Earnings announced in May. Sales were down to $8.4 million from $9.7 million last year, but they made money this year, $.03 a share versus a loss of $.10 last year. Margins expanded to 55% and cash and investments were $1.40 per share. Our valuation fell to $6.01. Still trading at 38% of our valuation and has 60% of its market cap in cash.
Down 25%, BUY
Extreme Networks (EXTR-Recommended 3/22/2010)
Buy Price-$3.18 (Was $3.04 before adding another $10,000)
Valuation-$6.31 (was $7.01, $6.72, $6.45, $5.67, $7.36, $7.23, $7.31, $6.82, $6.81)
Closed at $3.50 down $.09.
Earnings announced in May. Sales fell to $73.4 million from $75.7 million, but they earned $2.3 million versus a $6.8 million loss last year. Cash per share stayed at $1.56 and our valuation fell to $6.31 on the sales decline. They are projecting next quarter at sales of $82-$90 million and EPS over $.10.
Starboard owns 9.7%, Soros 8.8% and Blackrock owns 5.5% of EXTR.
Up 10%, BUY
Gravity Company Ltd. (GRVY-Recommended 1/18/2010)
Buy Price- $1.45 per ADS (Was $1.68 before double up)
Valuation $5.52-(Was $5.00, $5.39, $5.33, $5.61, $5.73, $4.38, $4.44, $5.15)
Closed up $.01 at $1.73
Now trading below cash value again.
Q1 earnings announced in May. Nice. Revenues were $14.4 million and they made $1 million or $.04 per ADS. Cash was $48 million or $1.74 per share. No update on how Ragnarok 2 was doing or rumored Face Book games. Short term holders were disappointed as the stock fell. We are thrilled that cash and revenues went up from last quarter and our valuation rose to $5.52.
Ragnarok was commercially released in Korea on March 26th.
Up 19%, BUY
AEterna Zentaris (AEZS-Recommended 6/20/2009)
Buy price $1.42 (was $1.78 before adding another $10,000, $1.82 before double up)
Closed at $.47 up $.02
AEZS announced that Perifosine failed in April. Carnage followed. Hmm, this will teach us a lesson to not recommend speculations any more. We are still holding ours as a lottery ticket.
Earnings out in March. Revenues for the quarter were $12.6 million, up from $10 million last year. Net loss was $7.5 million compared to $6.6 million last year. The net loss for the year was $29 million. Cash stood at $47 million and they continue to sell more stock. They sold another 3.6 million in 2012 so far and raised $6.4 million.
Speculative for sure.
Down 67%, HOLD
Spectranetics (SPNC-Recommended 9/2/2006)
Buy price $5.68 (was $8.90, $9.40 before adding $10,000, and was $10.65 before double up),
Valuation –$14.00 (was $12, $10)
Closed down $.10 at $10.89
A Board member bought 6,000 shares on May 25th, at just over $9.90. Good show of support at this level.
Earnings announced in May. Sales up 10% to $33.3 million and they broke even. Gross margins improved to 73%. SPNC also received FDA approval on the GlideLight laser Sheath which makes it easier to extract pacemaker leads.
Guidance for 2012 is unchanged– a 5-7% increase in revenues and $.04-$.08 in earnings per share, excluding two new product introductions anticipated for mid year introductions.
This company needs to be sold so that someone can take advantage of their 70%+ gross margins and enjoy some profits.
Up 92%, HOLD
Mediware (MEDW-Recommended 6/4/2007)
Buy Price $6.33, (was $6.52, $6.67 ($10,000 added), $6.98 after double up)
Valuation $19.24 (was $18.15, $17.96, $18.34, $16.07, $15.04, $14.23, $15.02, $14.35, $12.13, $12.57, $12.29, $11.90, $11.30, $11.48, $11.47 $10.99, $10.28, $13.32, $12.89, $13.40)
Closed down $.14 at $13.77
Earnings announced in May. Another good report. Revenues increased 22% and they made $.22 per share compared to $.17 last year. Cash is closing in on $4.50 a share ($4.42). Our valuation rose to $19.24.
All we read is that medical records will be a hot area, so MEDW looks like the place to be.
Up 117%, HOLD
Inuvo (INUV (was-VTRO, MIVA)-Recommended 10/21/2007)
Buy Price $8.15 (Was $11.90 before adding another $20,000, $13.10 before another $10,000 and was $15.00 before double up),
Valuation $1.84 (was $8.04, $10.91, $12.42, $14.23, $14.76, $12.40, $12.55, $10.85, $8.25, $9.45, $28.05, $32.10, $34.20, $37.90, $37.95)
Closed at $.66 down $.03
Earnings announced in May. The quarter only contained 1 month of combined operations after the merger. Sales for the quarter were $8.8 million and they reported $.2 million of adjusted EBITDA. The actual loss was $1.8 million. Our valuation plummeted to $1.84 a share based on the reported numbers. Our “guesstimate” valuation for a full quarter of combined operations is $3.59.
Down 88% HOLD
Angeion Corporation (ANGN-Recommended 8/28/2008)
Buy Price-$3.82 (was $5.15 before $10,000 added)
Valuation $11.95 (was $13.36 $15.90, $13.13, $13.19, $13.60, $15.00, $13.06, $12.15, $11.29, $11.73, $11.47, $11.16, $9.53, $13.30, $13.03)
Closed down $.22 at $5.59
The CEO bought 3,400 shares at $5.73 on June 13th.
Earnings announced in June. Hmmm. Sales were down from $6.8 million last year to $6.3 million. They lost $.4 million versus $.1 million last year. Not great, but they blamed it on a few large customers pushing out some orders into the current quarter. We’ll see soon, cause then this quarter should be a barn burner. Our valuation slipped to $11.95 ($13.19 last year). Cash was $2.45 per share versus $2.42 last quarter. They also disclosed that they had entered into a Letter of Intent (LOI) to sell their New Leaf business and were going to change their name to MGC Diagnostics Corporation. Well at least that sounds like a medical company.
If this company could just show a bit of growth I think we would see $10 in short order—if.
Blueline Partners still owns 7.6% of ANGN and ought to be pushing on the company to do something about the stock price.
While ANGN is still trading at less than ½ our valuation, we are switching to a HOLD until we gets some results or news that improves the prospects here.
Up 46%, HOLD
OB-abies (Bulletin Board Listed Stocks)
As proven by OPTIO, patience is necessary with these stocks.
ARI Networks (ARIS.ob-Recommended 8/19/2006)
Buy price $1.61 (Was $1.78 before another $10,000 added, was $2.06 before double up),
Valuation $6.13 (was $5.82, $5.81, $5.72, $5.65, $5.39, $4.86, $5.60, $5.73, $5.54, $5.74, $5.96, $4.72, $5.19, $5.66, $5.63, $5.61, $5.71, $5.49, $5.34, $5.03, $5.28, $5.28, $5.21)
Closed at $1.55 up $.25
Earnings announced in June. Not bad. Sales were up 7% to $5.7 million and they made $.03 a share down from $.07 last year as they spent more on technology infrastructure, investor relations and product development.
Our valuation moved up to $6.13—the highest ever since we have been following the stock. No one cared as the stock didn’t trade after the earnings announcement. Looks like they need to even spend more on investor relations and PR.
Now down 4%, BUY, Still a Huge valuation gap here.
Rand Worldwide (RWWI.ob (Was Avatech, AVSO.ob)-Bought November 28, 2005)
Buy price $.79 (Was $.93, $.99 and $1.19 before adding $10,000-each time),
Valuation $2.55 (was $2.08, $2.09, $2.12, $2.60, $2.40, $1.90, $2.26 $3.07, $3.03, $2.38, $2.57, $2.81, $2.78, $3.30, $3.76, $4.00 $3.41, $3.05, $2.53, $3.25, $3.29 $2.69, $3.36, $3.81)
Stock closed at $.80, down $.02
Earnings announced in May. Not bad. While sales were down to $22 million from $27 million last year (last year included a one big order), they made $.03 a share compared to $.04 last year. Margins increased to just over 50% from 47% last quarter. Our new valuation is $2.55 a share, down $.05 from last year.
Peter Kamin the new Chairman of the Board filed a 13D in March disclosing an 11% ownership state. Interesting as one would file a 13G if their intention was to just be a passive investor. Maybe as Chairman he will do SOMETHING to get the share price up.
RWWI announced an acquisition in March, but gave no financial details. “If a tree falls in the forest but there is no one around to hear it, dies it make a sound”? Seems like the company is making no effort to get this company known to the investment community. We have been in this one a LONG time and are getting impatient.
Market cap of $41 million for an $90 million in sales company with 50% margins and not losing money, just too cheap.
Our valuation is 3X the current price.
Up 1%, HOLD
CTI Holdings (CTIG.ob-Recommended 2/25/2006)
Buy price $.27 ask,
Valuation $1.34 (Was $1.37, $1.36, $1.23, $.91, $1.21, $.71, $.83, $.88 $.96, $.93, $.75, $.85, $1.57, $1.40, $1.29, $1.38, $1.31, $1.38, $1.29, $1.42, $1.28 $1.13, $1.05, $.82)
Ask price $.26, closed at $.23.
CTIG announced a product deal with Mitel in June. Any PR is good news here.
A Director purchased 30,000 shares on May 23rd at $.25 a share. Not a lot of money but a good sign that things are going well.
Earnings announced in May. Sales were up $250k over last year to $4.4 million and they made $113k versus a loss of $342k last year. Cash rose to $3.7 million or $.13 per share. Our valuation fell $.03 to $1.34 but this is up from $.91 a year ago. Three profitable quarters in a row.
At a $8 million market cap, this is stupidly cheap. Their intellectual property is probably worth 3 times this price. They need to liquefy this value somehow.
Still an “undercover” company and stock.
Down 4%. BUY
Lotus Pharmaceuticals (LTUS.ob-Recommended 12/3/2007)
Buy price $1.68 (Was $1.80 before $10,000 adder, $2.16 before double-up)
Valuation-$.85 (Was $1.05, $2.43, $4.11, $4.84, $4.98, $4.60, $3.82, $4.00, $3.68, $3.12, $3.98, $4.44, $3.22, $2.12, $4.56, $4.16)
Closed at $.04, unchanged.
Now LTUS announced in April that they have no money for audits and SEC filings. Hammered down to less than a nickel a share. Can you spare them some money? Not worth selling at this point until we need tax losses. Maybe something good will happen. What a disaster. No more Chinese stocks for us, no matter how compelling the valuation.
Oiy! Lotus announced in January that they had “sold” their Mongolian land. They get nothing for it and give up 3 drugstores in Bejing and $7 million of receivables. Not good as reflected on the huge (percentage wise at least) drop in the stock. This has indeed become a cheap lottery ticket. 25 shares for a buck. We are licking our wounds on this one, but will just wait it out. It may go to $0, or may hang around in the penny stock range for a while. The move into the new building has commenced and the warehouse (supposedly critical to selling in Bejing) will be functional by March and production to start by September.
Earnings announced in November. Revenues were up slightly over last year at $19 million versus $18.3 last year, but gross margins remained low and they made $2.1 million of $.04 per share compared to $.25 last year. Our valuation fell again to $.85.
Down 98%, HOLD